Stockscreener 앱 받기
101.55
0.54%
0.55
시장 영업 전:
101.55
전일 마감가:
$101.00
열려 있는:
$100.66
하루 거래량:
868.71K
Relative Volume:
0.92
시가총액:
$6.19B
수익:
$521.31M
순이익/손실:
$-23.36M
주가수익비율:
-212.40
EPS:
-0.4781
순현금흐름:
$54.87M
1주 성능:
+6.36%
1개월 성능:
-0.62%
6개월 성능:
+51.45%
1년 성능:
+101.41%
1일 변동 폭
$100.01
$103.36
1주일 범위
$93.81
$104.44
52주 변동 폭
$47.89
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
101.55 | 6.16B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Canada
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - lincolnjournal.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK
Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India
Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan
CenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Clearbridge Investments LLC - MarketBeat
Mirum (MIRM) President and COO exercises options, boosts direct share holdings - Stock Titan
5,000-share resale notice for MIRM (NASDAQ: MIRM) affiliate; prior sale noted - Stock Titan
Mirum Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates Significantly, Shares Edge HigherEarnings Quality Analysis - newsline.com
Mirum Pharmaceuticals (MIRM) Edges Higher as Bulls Test Resistance Near $98BPI Bear Confirmed - newsline.com
Mirum Pharmaceuticals, Inc. Balance Sheet – XETR:08D - TradingView
EBITDA of Mirum Pharmaceuticals, Inc. – XETR:08D - TradingView
Discipline and Rules-Based Execution in MIRM Response - Stock Traders Daily
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report? - Yahoo Finance
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth - Investing.com
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - BioSpace
Mirum and Incyte to present FOP drug trial results at ENDO 2026 - Investing.com Canada
Mirum and Incyte to present zilurgisertib study results at ENDO 2026 - StreetInsider
Mirum Pharmaceuticals (MIRM) Reports Positive Phase 2b Data for Volixibat in PSC at EASL Congress - Insider Monkey
Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing - Moomoo
HC Wainwright & Co. Maintains Mirum Pharmaceuticals (MIRM) Buy Recommendation - MSN
Mirum director Saira Ramasastry sells $397,700 of company stock By Investing.com - Investing.com South Africa
Insider Sell: Saira Ramasastry Sells 3,977 Shares of Mirum Pharm - GuruFocus
Mirum CEO Peetz sells $2.88m in stock after exercising options - Investing.com Nigeria
Mirum director Saira Ramasastry sells $397,700 of company stock - Investing.com
Mirum CEO Peetz sells $2.88m in stock after exercising options By Investing.com - Investing.com India
Mirum (MIRM) director converts 3,977 restricted stock units into common shares - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Mirum Pharmaceuticals (MIRM) director converts 3,977 RSUs into 9,680-share holding - Stock Titan
Mirum Pharmaceuticals (MIRM) director sells 3,977 shares under 10b5-1 plan - Stock Titan
MIRM Initiated Coverage by Citigroup -- Rating Set to Buy - GuruFocus
Insider sale and option exercise — MIRM: 40,985 shares sold, 30,000 planned - Stock Titan
3,977-share planned restricted-stock sale by MIRM (NASDAQ: MIRM) - Stock Titan
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline - Investing.com
Citizens reiterates Mirum Pharmaceuticals stock rating on pipeline By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Pushes Higher, Approaches Key ResistanceBullish Percent Index - newsline.com
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 - Weekly Voice
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mirum Pharmaceuticals Inc 주식 (MIRM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Jun 08 '26 |
Sale |
93.82 |
5,000 |
469,077 |
44,788 |
| Radovich Peter | PRESIDENT AND COO |
Jun 05 '26 |
Option Exercise |
19.19 |
16,988 |
326,000 |
57,260 |
1.27%
1.43%
자본화:
|
볼륨(24시간):